Semaglutide Significantly Improves Chronic Kidney Disease Semaglutide Significantly Improves Chronic Kidney Disease
The landmark FLOW study shows the benefits extend to kidney, cardiovascular, and mortality outcomes in high-risk patients with type 2 diabetes and CKD.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 25, 2024 Category: Consumer Health News Tags: Nephrology News Source Type: news

Ozempic Protects Kidneys, Boosts Survival in Diabetes Patients With CKD
(MedPage Today) -- For people with type 2 diabetes and chronic kidney disease (CKD), semaglutide (Ozempic) reduced the risk of major kidney events and death from cardiovascular causes, the phase III FLOW trial showed. Added to usual care, the... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 24, 2024 Category: Cardiology Source Type: news

What's the Goal in Treating Type 2 Diabetes? What's the Goal in Treating Type 2 Diabetes?
Anne Peters discusses the differences in the newly published American College of Physicians and the American Diabetes Association guidelines for treating type 2 diabetes.Medscape Diabetes & Endocrinology (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 23, 2024 Category: Cardiology Tags: Diabetes & Endocrinology Commentary Source Type: news

Balance performance, falls-efficacy and social participation in patients with type  2 diabetes mellitus with and without vestibular dysfunction - Komalasari DR, Vongsirinavarat M, Hiengkaew V, Nualnim N.
BACKGROUND: The performance of balance is an important factor to perform activities. The complications of type 2 diabetes mellitus (T2DM), especially vestibular dysfunction (VD), could decrease balance performance and falls-efficacy (FE) which consequently... (Source: SafetyLit)
Source: SafetyLit - May 23, 2024 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Experts reveal the one subtle warning sign of diabetes that can strike YEARS before other symptoms
Hungarian researchers claim they've found that patients at risk of Type 2 diabetes are up to 6-times likelier to have nerve damage linked to condition. (Source: the Mail online | Health)
Source: the Mail online | Health - May 22, 2024 Category: Consumer Health News Source Type: news

Experts demand obesity crackdown to cure sick note Britain after diabetes surge
Diagnoses of type 2 diabetes have surged among people under the age of 40, a Diabetes UK report reveals. (Source: Daily Express - Health)
Source: Daily Express - Health - May 21, 2024 Category: Consumer Health News Source Type: news

Pediatricians Reverse Decades-Old Advice Against HIV-Positive Mothers Breastfeeding
People with HIV can breastfeed their babies, as long as they are taking medications that effectively suppress the virus that causes AIDS, a top U.S. pediatricians’ group said Monday in a sharp policy change. The new report from the American Academy of Pediatrics reverses recommendations it had in place since the start of the HIV epidemic in the 1980s. It recognizes that routinely prescribed drugs can reduce the risk of transmitting HIV via breast milk to less than 1%, said Dr. Lisa Abuogi, a pediatric HIV expert at the University of Colorado and lead author of the report. [time-brightcove not-tgx=”true...
Source: TIME: Health - May 20, 2024 Category: Consumer Health News Authors: JONEL ALECCIA / AP Tags: Uncategorized News Desk wire Source Type: news

Study Identifies Several Onychomycosis Risk Factors Study Identifies Several Onychomycosis Risk Factors
Tinea pedis, chronic kidney disease, peripheral vascular disease, and type 2 diabetes were associated with an increased risk for onychomycosis in patients with onychodystrophy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 20, 2024 Category: Consumer Health News Tags: Dermatology Clinical Summary Source Type: news

Yet Another Benefit for Metformin?
(MedPage Today) -- Metformin started for pre-diabetes also appeared to reduce patients' risk of developing gout, researchers found. Among 1,154 people with elevated hemoglobin A1c (HbA1c) just short of the threshold for type 2 diabetes who began... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 17, 2024 Category: Cardiology Source Type: news

Does Eating Food With Emulsifiers Increase T2D Risk? Does Eating Food With Emulsifiers Increase T2D Risk?
Food emulsifiers, a common ingredient in many ultraprocessed foods consumed by millions worldwide, increased the risk for incident type 2 diabetes.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - May 17, 2024 Category: Endocrinology Tags: Diabetes & Endocrinology Clinical Summary Source Type: news

Uphill Battle: Navigating the Complexities of Diabetes Management
Managing type 2 diabetes involves crucial lifestyle changes for blood sugar control, mental health support, weight management, nutrition therapy, stress management, physical activity, and glucose regulation. (Source: The Economic Times)
Source: The Economic Times - May 16, 2024 Category: Consumer Health News Source Type: news

Lilly's Once-Weekly Insulin Top-Line Results Show Benefit Lilly's Once-Weekly Insulin Top-Line Results Show Benefit
Phase 3 data for efsitora alfa showed noninferiority to once-daily basal insulins in two studies of people with type 2 diabetes.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - May 16, 2024 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase Ib results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity
Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a clinically meaningful and statistically significant mean placebo-adjusted weight loss of 18.8% (p< 0.001)At week 24, 100% of CT-388 treated participants achieved>5% weight loss, 70% achieved>15% and 45% achieved>20% weight lossIn a subgroup with pre-diabetes at baseline, CT-388 treatment normalised glycemia in all patients, indicating its strong impact on glucose homeostasisNo new or unexpected safety signals were detected. Overall, CT-388 demonstrated a safety and tolerability profile consistent with its drug classBasel, 16 May 2024 - Roc...
Source: Roche Investor Update - May 16, 2024 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase Ib results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity
Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a clinically meaningful and statistically significant mean placebo-adjusted weight loss of 18.8% (p< 0.001)At week 24, 100% of CT-388 treated participants achieved>5% weight loss, 70% achieved>15% and 45% achieved>20% weight lossIn a subgroup with pre-diabetes at baseline, CT-388 treatment normalised glycemia in all patients, indicating its strong impact on glucose homeostasisNo new or unexpected safety signals were detected. Overall, CT-388 demonstrated a safety and tolerability profile consistent with its drug classBasel, 16 May 2024 - Roc...
Source: Roche Media News - May 16, 2024 Category: Pharmaceuticals Source Type: news

Soup and shake diets to be rolled out nationwide by NHS in £13m project to reverse type 2 diabetes
Trials have proved the programme, which supports dieters in cutting down to 800 calories a day, can be 'truly life-changing'. Initial results found around half went into remission. (Source: the Mail online | Health)
Source: the Mail online | Health - May 14, 2024 Category: Consumer Health News Source Type: news